Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany,...
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
August 01, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation...
Prostate Cancer Nuclear Medicine Diagnostics Market to Hit $1,315.66 million by 2028 at 10.6% CAGR - Says, The Insight Partners
July 25, 2022 10:30 ET
|
The Insight Partners
New York, July 25, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global...
Immunocore Announces $140 Million Private Placement Financing
July 18, 2022 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq:...
Monoclonal Antibodies for Oncology Global Market Report 2022
July 08, 2022 05:43 ET
|
Research and Markets
Dublin, July 08, 2022 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies for Oncology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report provides detailed...
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma
June 03, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous...
Dermatology Devices Market to Hit USD 23.43 Billion By 2028; Dermatology Devices Industry CAGR of 11.5% Between 2022-2028; Exclusive Insight Report by Vantage Market Research
May 05, 2022 08:03 ET
|
Vantage Market Research
WASHINGTON, May 05, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Dermatology Devices Market finds that Rising incidence of skin disorders, increasing awareness on...
Skin Grafting System Market Size Worth $1.34Bn, Globally, by 2028 at 7.1% CAGR - Exclusive Report by The Insight Partners
April 29, 2022 06:16 ET
|
The Insight Partners
New York, April 29, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Skin Grafting System Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product...
Advanced Dermatology and Cosmetic Surgery Acquires Maragh Dermatology, Surgery and Vein Institute
April 05, 2022 09:00 ET
|
Advanced Dermatology and Cosmetic Surgery
WASHINGTON, April 05, 2022 (GLOBE NEWSWIRE) -- Advanced Dermatology and Cosmetic Surgery announces today Maragh Dermatology, Surgery and Vein Institute, (Maragh Dermatology), has joined its brand...
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
February 16, 2022 07:30 ET
|
InflaRx N.V.
In vilobelimab and pembrolizumab combination arm, the three patients enrolled in the first dosing cohort have been treated for 36 days with no safety concernsSteering Committee unanimously voted to...